TCT.13: TAVR, stents & more on docket for late-breakers

Candace Stuart | | Cardiovascular Business | Interventional Cardiology

The Transcatheter Cardiovascular Therapeutics (TCT) unveiled its lineup of clinical trials to be presented at its 2013 scientific sessions. The conference, TCT’s 25th, is scheduled to take place Oct. 28-Nov. 1 in San Francisco.

Below is the schedule:

Oct. 29

Late-breaking clinical trials

  • SAFE-PCI: A prospective, registry-based randomized trial of radial vs. femoral vascular access in women undergoing diagnostic cardiac catheterization and PCI
  • COREVALVE EXTREME RISK: A prospective registry study of transcatheter aortic valve replacement with a self-expanding transcatheter heart valve in patients with severe aortic stenosis
  • SORT-OUT VI: A prospective, randomized “all-comers” trial of biodegradable polymer-coated biolimus-eluting stents vs. biocompatible polymer-coated zotarolimus-eluting coronary stents

Oct. 30

Late-breaking clinical trials

  • EUROMAX: A prospective, randomized trial of ambulance initiation of bivalirudin vs. heparin ± glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI
  • NORDIC-BALTIC BIFURCATION IV: A prospective, randomized trial of a two-stent strategy vs. a provisional stent strategy in true coronary bifurcation lesions
  • TRYTON: A prospective, randomized trial of a dedicated sidebranch stent vs. a provisional stent strategy in true coronary bifurcation lesions

First report investigations

  • LEVANT 2: A prospective, randomized trial of a paclitaxel-coated balloon vs. standard balloon angioplasty in diseased femoropopliteal arteries
  • RIBS V: A prospective, randomized trial of paclitaxel-coated balloon angioplasty vs. everolimus-eluting stents in bare metal in-stent restenosis
  • SMART-CASE: A prospective, randomized trial of conservative revascularization vs. aggressive revascularization in patients with intermediate lesions undergoing PCI with angiographic guidance alone
  • HeartFlowNXT: A prospective, registry evaluation of noninvasive FFRCT vs. invasive FFR
  • ADVISE II: A prospective, registry evaluation of iFR vs. FFR
  • CHILL-MI: A prospective, randomized trial of therapeutic hypothermia in patients with acute myocardial infarction undergoing primary PCI

Oct. 31

Late-breaking clinical trials

  • OPTIMIZE: A prospective, randomized trial of three months vs. 12 months of dual antiplatelet therapy After PCI
  • ARCTIC-INTERRUPTION: A prospective, randomized trial of two years vs. one year of dual antiplatelet therapy After PCI
  • DUTCH PEERS (TWENTE II): A prospective, randomized “all-comers” trial of zotarolimus-eluting stents vs. everolimus-eluting coronary stents

First report investigations

  • REPRISE II: A prospective registry study of transcatheter aortic valve replacement with a repositionable transcatheter heart valve in patients with severe sortic stenosis
  • FREEDOM: A prospective, randomized trial of first-generation DES vs.  CABG in insulin and non-insulin treated diabetic patients
  • HYBRID: A prospective, randomized trial of hybrid coronary revascularization vs. standard surgical revascularization in multivessel disease
  • TRANSLATE-POPS: A prospective, cluster-randomized trial of routine platelet function testing in patients undergoing PCI
  • GIANT: A prospective registry study of CYP2C19 genetic profiling for thienopyridine management after primary PCI in acute myocardial infarction
  • TATORT-NSTEMI: A prospective, randomized trial of thrombus aspiration in thrombus-containing culprit lesions in Non-ST-Segment Elevation Myocardial Infarction

Candace Stuart, Contributor

Related Content

Cardiologists reflect on developing primary PCI in face of criticism and pushback
How TAVR valve choice impacts outcomes when treating type 1 bicuspid AS
IVUS-guided PCI reduces risks in patients with diabetes
Medtronic using AI to identify more TAVR patients in need
SAVR linked to higher 10-year survival rate than TAVR for low-risk patients
LAAC with Watchman FLX reduces bleeding risks after AFib ablation

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."